Drugs and patents in ATC class A10BK - Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
DAPAGLIFLOZIN	dapagliflozin
FARXIGA	dapagliflozin
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	dapagliflozin; metformin hydrochloride
XIGDUO XR	dapagliflozin; metformin hydrochloride
>Tradename	>Generic Name

Last updated: July 23, 2026

Market dynamics and patent landscape for ATC Class A10BK (SGLT2 inhibitors)

ATC A10BK SGLT2 inhibitors is dominated by four commercial pillars in the US and EU: dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin. Patent coverage is split between (1) active-ingredient process and intermediate patents, (2) solid form and tablet/combination formulation patents, and (3) expansion IP on renal and cardiovascular outcomes (method-of-use, dosing regimens, and trial-driven claims). Near-term generic and biosimilar risk is concentrated in earlier-introduced molecules where composition-of-matter or key formulation patents have largely lapsed or are close to expiry, while brand-specific exclusivity extensions remain material through 2030+ via combinations, additional indications, and second-generation crystalline or dosage patents.

Commercial posture. SGLT2 inhibitor penetration is driven by cross-class guideline placement in type 2 diabetes and by label expansion into chronic kidney disease (CKD) and heart failure (HF). This increases patent “stickiness” because clinical outcomes claims are harder for generics to bypass without design-around or narrow Paragraph IV strategy. For business, the core IP question is less “can a generic copy the tablet” and more “can a generic launch avoid infringement while matching label-adjacent outcomes and approved dosing.” In practice, the main constraints are formulation and method-of-use coverage and the inability to market claim-adjacent indications until safe harbor and carve-outs are established.

What is the patent landscape for SGLT2 inhibitors (ATC A10BK) across dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin?

Answer. The SGLT2 inhibitor estate is layered: composition-of-matter and core synthetic route patents set long horizons for each active ingredient, while formulation and indication expansion patents narrow and prolong exclusivity window-by-window by jurisdiction.

Layer 1: Active ingredient composition and process route patents

SGLT2 programs began with early 2000s medicinal chemistry and crystallography. For each molecule, later-expiring patents typically fall into:

Intermediate and process patents covering synthesis steps, catalysts, solvents, and purification.
Solid-state form patents covering specific polymorphs, hydrates, solvates, and crystal morphologies used in commercial manufacturing.
Manufacturing method patents (scale-up, purification, drying, and milling conditions).

These patents are often jurisdictionally fragmented. A route/process patent may expire earlier in one country while a solid form patent stays live elsewhere, creating asymmetric generic timelines.

Layer 2: Formulation patents (tablets, dosing, and combinations)

SGLT2 inhibitors are usually sold as once-daily tablets and later as fixed-dose combinations. Formulation patents commonly cover:

Specific excipient systems and film-coating compositions.
Particle size distributions and granulation methods.
Stability improvements and humidity/thermal behavior.
Fixed-dose combination compositions (e.g., with metformin, or other diabetes agents depending on the molecule’s portfolio).

Because formulation patents tend to be composition-specific and manufacturing-linked, they are a common basis for enforcement and settlement leverage.

Layer 3: Method-of-use patents (outcomes, CKD, and HF)

Method-of-use patents track label expansions and payer-driven clinical usage. In many cases the claims aim at:

Reducing risk of CKD progression and renal endpoints in defined populations.
Reducing risk of CV death or HF hospitalization in defined HF phenotypes.
Specific dosing or titration regimens mapped to trial protocols.

These are critical for market dynamics because even if a generic can launch for diabetes, it may be structurally blocked from full label-adjacent promotion in jurisdictions where method-of-use patents remain in force.

When do SGLT2 inhibitor patents lose exclusivity in the US and EU?

Answer. The exclusivity timeline is molecule-specific. Earlier-introduced agents face first generic erosion, while later entrants and combination franchises retain longer protection. The practical market effect is staggered erosion by drug, dose strength, and geographic scope.

Typical timeline mechanics used in SGLT2 programs

Regulatory data exclusivity (where applicable) and initial New Chemical Entity exclusivity set a baseline.
Patent term from priority date and patent term adjustments vary by jurisdiction.
Secondary patents extend practical exclusivity even after early composition/pivots expire, especially for formulations and method-of-use.
Litigation settlements can extend market absence of generics even where patents are likely to be invalid or non-infringing.

Commercial timing outcomes

US: The US market usually sees erosion aligned to Paragraph IV strategy on the earliest high-value patents plus settlement-driven “soft launch delays.”
EU: Member-state enforcement and national validations can delay generic entry even when patent expiries are close.

Because the question is asked at the class level (ATC A10BK), the key business read is not a single expiry date but the sequencing: earlier molecules erode first in diabetes-only use cases; CKD and HF method-of-use coverage sustains brand leverage longer across all molecules.

Which patents are most often asserted against generics for SGLT2 inhibitors (composition vs formulation vs method-of-use)?

Answer. In SGLT2, infringement assertions most commonly pivot between formulation patents (solid state and tablet composition) and method-of-use patents (label-adjacent outcomes). Composition-of-matter and core process patents tend to anchor the earliest enforcement but are harder to litigate quickly once design-around pathways exist.

Formulation and solid form: why they matter

Generic manufacturers can sometimes design a different solid form or different crystallization approach, but the cost and feasibility are higher for SGLT2 due to:

commercial-scale solid state controls,
tight specs on polymorph and particle properties, and
linkages between solid form and bioavailability.

Method-of-use: why they matter

Method-of-use patents can restrict marketing and promotion even when a generic has an AB-rated label. This raises generic “commercial usability cost,” which reduces incentive to launch aggressively during the protection window.

How many patents cover each SGLT2 inhibitor and how strong is the estate?

Answer. The estate size and strength vary materially by molecule and by whether the commercial portfolio includes combinations and expanded outcomes indications. At the class level, strength is highest where:

there are multiple independent claim families spanning solid state, formulation, and outcomes,
the claims align with broad label indications, and
there is a history of successful enforcement or settlements.

What “strong” looks like in enforcement practice

Multiple non-overlapping patent families that each cover an essential element (drug substance identity, solid form/manufacturing, dosage form, and clinical endpoint use).
Jurisdictional breadth: core patents validated in multiple EU states plus US counterpart filings.
Late-stage patent additions tied to trial endpoints and updated clinical protocols.

For business decisions, the decisive metric is not total patent count alone. It is the presence of at least one enforceable, non-design-around path that a generic cannot easily avoid while still selling into the main prescriber and payer label use.

What patent litigation affects SGLT2 inhibitor market entry (Paragraph IV, injunctions, and settlements)?

Answer. US market entry risk is concentrated in Paragraph IV challenges against branded Orange Book-listed patents for each molecule and dose strength. Settlements often shift the launch date rather than trigger full invalidation outcomes.

Litigation pattern common to SGLT2 class

Generic files Paragraph IV against one or more listed patents covering formulations and method-of-use.
Brand responds with infringement suits and seeks temporary restraining orders and preliminary injunction leverage where permitted.
Parties settle with:
- delayed launch date,
- covenants not to sue on certain patents, and
- carve-outs tied to specific dosages or labeling language.

Business impact

Even when a generic’s legal case survives early motions, a settlement can still establish a de facto exclusivity extension. For investors and licensing teams, the settlement “shadow” is often as important as the nominal patent expiry.

What is the Orange Book status of SGLT2 inhibitors in the US?

Answer. Each marketed SGLT2 inhibitor is tied to an Orange Book listing set for the branded drug product and any separately protected patents that qualify for listing. The Orange Book status functions as the map for Paragraph IV eligibility and defines which patents are at risk for generic “180-day exclusivity” triggers.

Practical Orange Book read-through

If the key listed patents are tied to formulations or method-of-use, generic entry is commercially constrained even if the product can be manufactured.
If only process patents remain after key solid form and formulation expiry, infringement risk can drop but marketability still hinges on labeling and indication carve-outs.

What formulation patents protect SGLT2 tablets and how do they shape generic design-around?

Answer. SGLT2 formulation protection commonly targets:

solid state forms (polymorphs, hydrates, solvates),
tablet compositions (excipient systems, coatings, compression parameters), and
manufacturing-linked specs that indirectly govern polymorph outcomes.

How design-around typically works

Using alternative crystal forms or seeding strategies to avoid specific solid form claims.
Changing granulation and drying parameters to achieve the target stability and dissolution profile without infringing a specific formulation claim.
Using different excipient compositions where claims are tightly drafted.

Why this increases barriers

Generic development becomes a higher-dimensional project: it is not only bioequivalence but also IP clearance against multiple claim families. That increases time-to-market and settlement propensity.

How do method-of-use patents on CKD and heart failure affect generic commercialization of SGLT2 drugs?

Answer. Method-of-use patents can prevent full-market promotion for CKD and HF indications while diabetes indications may still be available depending on claim scope and labeling carve-outs.

CKD and HF claims raise the “label utility” issue

If generics can sell only under diabetes-only promotion, payer adoption slows.
If generics are constrained from prescribing for CKD or HF endpoints, brand share can remain high even after diabetes label erosion.

This is why SGLT2 exclusivity remains economically significant long after first patent expiry events.

How does the patent estate of SGLT2 inhibitors compare: dapagliflozin vs empagliflozin vs canagliflozin vs ertugliflozin?

Answer. The relative strength tends to follow portfolio maturity and the number of label-expanding outcomes programs with associated patent claim families. Dapagliflozin and empagliflozin usually show the highest breadth in outcomes-linked patent coverage. Canagliflozin’s estate remains relevant through solid form and formulation families plus select outcomes claims. Ertugliflozin typically has a smaller commercial footprint, but still carries its own formulation and method-of-use families that can delay entry.

Key comparative business levers

Outcomes breadth: more CKD/HF-related claims increases market protection utility.
Combination products: fixed-dose combinations can create additional protected product lines.
Manufacturing controls: stronger solid-state and tablet formulation protection can extend practical barriers.

What biosimilar risk exists for SGLT2 inhibitors?

Answer. None. SGLT2 inhibitors are small-molecule drugs; biosimilars apply to biologics. Market entry risk is generic small-molecule challenge-driven, not biosimilar-driven.

What generic entry risks exist for SGLT2 inhibitors?

Answer. Generic entry risk exists across:

composition/formulation patents (solid form and tablet formulation),
process patents (manufacturing steps and intermediates), and
method-of-use patents (CKD/HF outcomes and specific patient subsets).

Risk increases when:

the most prominent formulation patents have expired,
the remaining patents are narrow (specific solid form not used commercially), or
prior litigation resulted in invalidation or carve-outs that reduce enforcement leverage.

How do settlement agreements and covenants not to sue influence SGLT2 competition?

Answer. Settlements in SGLT2 generic challenges often define a practical launch schedule. Even if a generic can legally enter earlier for certain strengths or indications, covenants and agreed labeling changes govern real-world uptake. The outcome is a staggered competitive ramp rather than an immediate price collapse.

Deal mechanics that matter commercially

launch date tied to the last expiring asserted patent family,
labeling carve-outs for CKD/HF claims,
agreed paragraph IV patent scope for future litigation.

Commercial dynamics: why SGLT2 exclusivity persists even as diabetes-only patents expire

Answer. The enduring economics are CKD and HF adoption. Prescribers and payers treat SGLT2 inhibitors as disease-modifying agents, not only glucose drugs. That links demand to outcomes evidence, which is reinforced by method-of-use claim families and by continued brand marketing under broad label indications.

Key takeaways

SGLT2 inhibitors (ATC A10BK) have a layered patent stack: active-ingredient substance and process, solid form and tablet formulation, and outcomes-linked method-of-use claims.
Practical market exclusivity is driven more by formulation and method-of-use coverage than by early composition patents alone.
US generic entry risk is Paragraph IV-focused on Orange Book-listed patents; settlements commonly delay launch and/or constrain labeling utility.
CKD and HF indications sustain brand value by reducing the commercial usability of generic launches even when diabetes-only entry pathways exist.
Biosimilar risk is not applicable; the competition vector is generic small molecules plus authorized generics and settlement-driven timing.

FAQs

1) Which patent families most often determine when a generic SGLT2 inhibitor can launch without injunction risk?

Those covering commercial solid-state form and tablet formulation, plus the broadest method-of-use claims aligned to CKD/HF label language.

2) Do SGLT2 fixed-dose combination products have separate IP barriers from the standalone drugs?

Yes. Combination compositions and dosing regimens usually have dedicated formulation and method-of-use claim sets that can extend exclusivity beyond the monotherapy.

3) Can a generic launch an SGLT2 inhibitor but avoid infringement by changing the crystalline form?

Often feasible only if the generic can show non-infringement against specific solid form claims while still meeting stability and bioavailability specifications.

4) How do labeling carve-outs affect payer access for generic SGLT2 inhibitors?

Carve-outs tied to CKD and HF endpoint claims can reduce reimbursement and guideline-concordant prescribing, limiting real-world uptake.

5) What are the highest priority patent risks for an SGLT2 licensing target?

The remaining live Orange Book-listed patents covering the drug product formulation and the method-of-use outcomes that match high-volume prescriber behavior.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
EMA. European public assessment reports (EPAR) for SGLT2 inhibitor products. European Medicines Agency. https://www.ema.europa.eu/en/medicines